SuperworthImmucell profit margin ICCC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 2.6%
- Operating margin, 12 months
- 12.6%
- Net margin on a year earlier
- −3.7 pts
- Peer median
- 8.4%
Over the twelve months to Jun 30, 2026, Immucell kept 2.6% of its revenue as net profit, with an operating margin of 12.6% and a gross margin of 40.3%.
Five years earlier its net margin was −2.7%.
The median for 10 healthcare stocks of a similar size is 8.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −3.8% | 6.0% | 41.4% |
| FY2024 | −8.1% | −6.2% | 30.0% |
| FY2023 | −33.1% | −32.9% | 22.1% |
| FY2022 | −13.4% | −12.4% | 41.2% |
| FY2021 | −0.4% | 1.3% | 45.0% |
| FY2020 | −6.7% | −9.0% | 44.7% |
| FY2019 | −9.4% | −7.0% | 49.1% |
| FY2018 | −21.1% | −13.2% | 47.3% |
| FY2017 | −1.6% | −2.3% | 50.1% |
| FY2016 | 5.3% | 9.3% | 56.8% |
| FY2015 | 11.9% | 20.7% | 61.1% |
| FY2014 | −2.2% | −2.7% | 58.6% |
| FY2013 | 2.0% | −0.3% | 50.9% |
| FY2012 | 1.7% | 4.5% | 56.7% |
| FY2011 | −8.0% | −12.4% | 55.1% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 2.6% | −3.7 pts | 12.6% | |
| Q1 FY26 | −1.8% | −0.8 pts | 8.4% | |
| Q4 FY25 | −3.8% | +4.4 pts | 6.0% | |
| Q3 FY25 | 8.4% | +24.4 pts | 8.4% | |
| Q2 FY25 | 6.2% | +23.7 pts | 6.1% | |
| Q1 FY25 | −1.0% | +17.3 pts | −0.8% | |
| Q4 FY24 | −8.1% | +24.9 pts | −6.2% | |
| Q3 FY24 | −16.0% | +22.7 pts | −13.7% | |
| Q2 FY24 | −17.4% | +20.9 pts | −16.7% | |
| Q1 FY24 | −18.3% | +14.9 pts | −17.8% | |
| Q4 FY23 | −33.1% | −19.6 pts | −32.9% | |
| Q3 FY23 | −38.7% | −35.0 pts | −39.2% |
Against its peers
Companies in Healthcare nearest Immucell's size, closest first, today.
| Company | Profit margin |
|---|---|
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| APTAlpha Pro Tech | 6.8% |
| ATNMActinium Pharmaceuticals | n/m |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| ELMDElectromed | 15.3% |
| NEPHNephros | 8.4% |
| Peer median | 8.4% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Immucell
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.